News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Amends Offer to Address Human Genome Sciences, Inc. (HGSI) Poison Pill



5/24/2012 7:29:56 AM

GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc. to address a poison pill mechanism its target put in place last week. Human Genome's plan, implemented as it reiterated its rejection of the offer on May 17, dilutes holdings should a third party attempt to buy up 15% or more of its stock without the board's support. GlaxoSmithKline said it has added a condition to its offer "requiring HGS to redeem the pill or, alternatively, GSK being satisfied in its reasonable judgment that the pill has been invalidated or is otherwise inapplicable to GSK's acquisition of HGS."

Read at The Deal.com
Read at RTT News
Read at Las Vegas Sun
Read at Fox News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES